Major-histocompatibility-complex-class-II-positive cells and interleukin-2-dependent proliferation of immune T cells are required to reject carcinoma cells in the guinea pig
- 1 September 1990
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 31 (5) , 297-304
- https://doi.org/10.1007/bf01740938
Abstract
Summary Tumor immunity induced by bacillus Calmette-Guérin was studied in the line 10 hepatocellular carcinoma (line 10) in the strain-2 guinea pig. Line 10 immunity was investigatedin vitro with a lymphocyte proliferation assay using line 10 tumor protein extracted with 3 M KCl andin vivo by adoptive transfer of line-10-immune spleen cells. Monoclonal antibodies against guinea pig leucocyte markers were used to block functional properties of the immune cells in order to determine which cell types or cell markers are involved in the immune response to the line 10 tumor.In vitro cells from the spleen, peripheral blood and regional lymph node of immune animals reacted with a proliferative response to line 10 protein. This antigen-specific response was caused by T cells and was regulated by major histocompatibility complex (MHC) class II molecules. In blocking experiments it was found that CT5 (anti-PanT), or MSgp4 [anti-(MHC class I antigen)] monoclonal antibodies did not block but some-times stimulated the proliferative response. The effect of H159 (anti-PanT) was irregular, while H155 [anti-(T helper)], and 5C3 [anti-(IL-2 receptor)] monoclonal antibodies blocked the response almost completely. We studied the relevance of the resultsin vitro obtained and found that mAb 5C3 [anti-(IL-2 receptor)] inhibited the adoptive transfer of line 10 immunity, suggesting that the rejection of line 10 cells is caused by a mechanism that is interleukin-2 (IL-2)-dependent. Moreover, complement lysis of MHC-class-II-antigen-positive immune spleen cells inhibited completely the rejection of the line 10 tumor cell challenge in the adoptive-transfer experiments. In conclusion, our data show that MHC class II molecules or cells possessing these molecules are involved in immunity against line 10 tumor cells, as (a) monoclonal antibodies against MHC class II antigens inhibited thein vitro proliferative response of T cells to tumor antigens and (b) removal of MHC-class-II-positive immune spleen cells abrogated the antitumor effect in the adoptive-transfer experiments. Interleukin-2-dependent proliferation of immune T cells is required for the rejection of line 10 tumor cells.Keywords
This publication has 34 references indexed in Scilit:
- Multichain Interleukin-2 Receptor: A Target for Immunotherapy in LymphomaJNCI Journal of the National Cancer Institute, 1989
- Interleukin-2 Receptor β Chain Gene: Generation of Three Receptor Forms by Cloned Human α and β Chain cDNA'sScience, 1989
- Functionally relevant membrane proteins of human and guinea-pig T lymphocytesMolecular Immunology, 1986
- The Interleukin‐2 Receptor, its Physiology and a New Approach to a Selective Immunosuppressive Therapy by Anti‐Interleukin‐2 Receptor Monoclonal AntibodiesImmunological Reviews, 1986
- Interleukin 2-driven T lymphocyte proliferation is dependent upon a surface antigen distinct from the interleukin 2 receptor: Requirements for inhibition of T-cell proliferation by monoclonal antibody 5C3Cellular Immunology, 1984
- Common and Specific Antigens on Two Tumor Cell LinesPublished by Elsevier ,1984
- MHC‐Restricted T Cell Activation: Analysis with T Cell HybridomasImmunological Reviews, 1983
- Monoclonal antibodies to guinea pig Ia antigens. II. Effect on alloantigen-, antigen-, and mitogen-induced T lymphocyte proliferation in vitro.The Journal of Experimental Medicine, 1980
- Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens.The Journal of Experimental Medicine, 1976
- Tumor-secific immunity to chemically induced tumors. Evidence for immunologic specificity and shared antigenicity in lymphocyte responses to soluble tumor antigens.The Journal of Experimental Medicine, 1975